Efficacy of Combined Hericium erinaceus Mycelium and Undenatured Type II Collagen in Reducing Osteoarthritis Progression in a Preclinical Animal Model.

HEM and UC-II reduced pro-inflammatory cytokines IL-1β and TNF-α in an OA animal model.

• The study used an anterior cruciate ligament transection (ACLT) model to induce OA.
• Both IL-1β and TNF-α levels were reduced following treatment with HEM, UC-II, and their combination.
• Reduction in these cytokines was associated with decreased cartilage degradation and bone loss.
• The combination of HEM and UC-II was investigated for additive or synergistic effects on cytokine suppression.

HEM and UC-II inhibited chondrolytic factors MMP-3, MMP-13, and ADAMTS5 in the OA model.

• MMP-3, MMP-13, and ADAMTS5 are matrix metalloproteinases and aggrecanase implicated in cartilage matrix degradation.
• Treatment with HEM, UC-II, and their combination reduced expression of these chondrolytic factors.
• Inhibition of these factors was linked to preservation of aggrecan and COL2A1 in cartilage tissue.
• ADAMTS5 reduction contributed to protection against aggrecan degradation specifically.

HEM and UC-II treatment preserved aggrecan and COL2A1 (type II collagen) in joint cartilage.

• Degradation of aggrecan and COL2A1 was inhibited in groups receiving HEM, UC-II, or their combination.
• Preservation of these cartilage matrix components was attributed to the reduction of pro-inflammatory cytokines and chondrolytic enzymes.
• The ACLT model was used as the preclinical standard for inducing OA-like cartilage degradation.
• Results suggest structural cartilage protection as a mechanism of action for the combined supplement.

HEM and UC-II reduced bone pain associated with ACLT-induced OA.

• Bone pain, a key functional outcome of OA, was measured in the ACLT animal model.
• Both individual and combined treatments with HEM and UC-II resulted in reduction of bone pain.
• Pain reduction was observed alongside decreases in inflammatory markers.
• The preclinical model used anterior cruciate ligament transection to replicate OA-associated pain.

The combination of HEM and UC-II prevented OA progression more effectively, supporting its use as a combined therapy.

• The study specifically investigated whether the combination of HEM and UC-II was more effective than either agent alone.
• Combined treatment blocked both cartilage breakdown and bone loss in the ACLT model.
• The combination was reported to prevent OA progression based on histological and biochemical outcomes.
• These findings provide preclinical evidence for using HEM and UC-II together for OA therapy.

Hericium erinaceus mycelium (HEM) is recognized as a functional food previously reported as beneficial for OA management.

• H. erinaceus is a large edible mushroom widely consumed in Asian countries.
• It has prior recognition as a functional food with reported benefits in OA supplementation.
• The mycelium form (HEM) was specifically used in this study, not the fruiting body.
• UC-II is described as 'a new nutraceutical ingredient' that has garnered interest for OA treatment.